Enzymatic Biostimulants: The Science Behind Superior Bioactivity — Chitosan Oligosaccharide, Alginate Oligosaccharide, Enzymatic Seaweed Extract & Fermented Protein Hydrolysate

1. Chitosan Oligosaccharide (COS)

Chitosan oligosaccharides are produced by the enzymatic hydrolysis of chitosan—a deacetylated derivative of chitin. The bioactivity of COS is governed by three structural parameters: degree of polymerization (DP), degree of deacetylation (DD), and the acetyl distribution pattern.

1.1 Proprietary Enzyme System

• Self-developed engineering strain with an enzyme activity of 1,500 U/mL—approximately 3× higher than the best reported values in literature.
• Acetic acid system: the only domestic COS producer using acetate-buffer enzymatic hydrolysis, enabling precise molecular-weight control.
• Self-sufficient enzyme production: 100 L → 1,000 L → 10,000 L triple-stage fermentation system; 1 mL fermentation broth yields 1.5 g COS powder.
• DP controllability: can produce DP2–3, DP2–5, or DP2–8 oligosaccharide profiles on demand.

1.2 Product Specifications

Why light color matters: A lighter color indicates a shorter enzymatic hydrolysis time and lower oxidative browning—meaning higher biological activity.

1.3 Cost Advantage

• Raw material: Exclusive supply agreement with a major Vietnamese chitosan factory; largest domestic chitosan annual purchase volume (130 tons in 2022).
• Spray drying: Largest domestic COS spray-drying unit (500 model, 500 kg water evaporation/hour)—lowest per-ton drying cost in China.
• Enzyme self-sufficiency: Proprietary strains eliminate enzyme procurement costs.

1.4 Quality Verification

Independent analysis by the National Pesticide Quality Supervision & Inspection Center (Shenyang Research Institute of Chemical Industry, SARCCI) confirmed:

• Chitosan oligosaccharide content: 93.4%
• Monosaccharide (glucosamine) content: only 0.03%
• Average MW 773 Da, consistent with HPLC data from Qingdao Marine Biomedicine Research Institute

2. Alginate Oligosaccharide (AOS)

Alginate is a linear copolymer of 1→4-linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) residues. Enzymatic cleavage by alginate lyase produces unsaturated oligosaccharides with a Δ^4,5 double bond at the non-reducing end—the structural basis for superior bioactivity.

2.1 Three Pillars of MacroAlga Alginate Lyase

2.2 Chemical vs. Enzymatic AOS

Chemical degradation (acid/alkali) of alginate produces saturated oligosaccharides via random glycosidic cleavage, which exhibit markedly lower bioactivity. Enzymatic β-elimination generates unsaturated AOS that:

• Induce plant defence genes at lower concentrations
• Stimulate root elongation and lateral root formation (DP2–4 optimal)
• Enhance salinity tolerance via osmotic-stress response pathways
• Exhibit antimicrobial activity against oomycete pathogens

2.3 AOS DP < 5: Optimal Bioactivity

Ion chromatography analysis confirms that MacroAlga AOS is a white powder produced from food-grade sodium alginate via enzymatic hydrolysis, followed by filtration and spray drying. The DP distribution is predominantly DP2, DP3 and DP4—the oligosaccharide range consistently reported in literature as possessing the highest biological activity. Competitor products typically span DP2–6 with broader, less active distributions.

• AOS with DP < 5 significantly enhances root growth and salinity tolerance.
• High PolyG specificity ensures superior formulation compatibility with fertilizers and micronutrients.
• Unsaturated terminal double bond (Δ^4,5) is the structural determinant of bioactivity—absent in chemically degraded products.

3. Enzymatic Seaweed Extract (KEYO® Series)

MacroAlga’s KEYO® enzymatic seaweed extract is produced from three distinct brown algal feedstocks—each selected for its unique phytohormone and polysaccharide profile.

3.1 Core Technological Advantages

3.2 KEYO® Product Line

           Ascophyllum nodosum                                   Ecklonia maxima                                     Fresh Laminaria japonica

3.3 Enzymatic Seaweed Process & Products

The enzymatic process adds only alginate lyase and cellulose enzyme—no chemical additives whatsoever. One ton of fresh kelp yields one ton of enzymatic seaweed extract liquid with an alginate oligosaccharide concentration of 25 g/L.

• Enzymatic kelp stock solution: Only alginate lyase and cellulose enzyme added; zero chemical inputs. 1 ton fresh kelp → 1 ton extract, AOS ≥ 25 g/L.
• Enzymatic kelp clear solution: Stock solution filtered through ceramic membranes; identical AOS content. Ideal as a base for chelated Ca/Mg and micronutrient foliar fertilizers.

4. Enzymatic & Fermented Protein Hydrolysate

4.1 Enzymatic Fish Protein Hydrolysate

4.2 Plasma Enzyme-Fermented Protein (Blood Peptide)

MacroAlga’s proprietary enzyme pretreatment + lactic acid fermentation process represents a unique two-stage bioconversion:

1. Plasma protein powder is first hydrolyzed with protease to generate low-molecular-weight peptides.
2. Carbon source is added, and 3 proprietary lactic acid bacteria (LAB) strains are inoculated.
3. Fermentation proceeds for 4–5 days, producing synbiotic biostimulants rich in bioactive peptides, free amino acids, and organic acids.

CTI Testing report (A2230097391101001C) confirms the nutritional profile of blood peptide powder: crude protein 93.88%, total amino acids 84.84%, lysine 9.35%, proline 3.01%, tryptophan 1.16%. Hemoglobin-derived heme serves as a precursor for the 5-aminolevulinic acid (5-ALA) pathway, directly supporting chlorophyll synthesis and photosynthetic efficiency under stress.

4.3 Chicken-Derived Peptide

MacroAlga’s chicken-derived peptide is produced via 100% enzymatic hydrolysis of poultry processing by-products, retaining complete amino acid nutrition. With an average molecular weight < 1,000 Da, the product ensures rapid phloem mobility and high bioavailability. The exclusive triple-process—enzymolysis + ultrafiltration + concentration—delivers high purity and solubility for both foliar and soil applications.

• Circular & cost-effective: Upcycling poultry waste into value-added peptides for optimal cost efficiency.
• Full amino profile: 100% enzymatic hydrolysis retains complete nutrition.
• High bioavailability: MW < 1,000 Da ensures rapid uptake.
• Cutting-edge purification: Exclusive triple-process for high purity and solubility.

5. Biostimulant Chelation Platform: Replacing Synthetic Ligands

Traditional micronutrient fertilizers rely on synthetic chelators such as EDTA, which face increasing regulatory restrictions due to poor biodegradability and environmental persistence. MacroAlga’s chelation platform replaces EDTA with biodegradable oligosaccharide and peptide ligands derived from its own enzymatic production lines—delivering metals in a plant-available form while simultaneously supplying bioactive COS and AOS.

5.1 Chelation Mechanism

Peptide and oligosaccharide ligands form stable 2:1 ligand:metal complexes at pH 5.5–6.5 under controlled mechanical stirring in fermenters. The resulting products combine the nutrient-delivery function of traditional chelates with the biostimulant activity of COS and AOS—a dual-action formulation impossible with EDTA-based systems.

5.2 Chelated Product Portfolio

5.3 Advantages Over EDTA Chelates

6. Why Enzymatic Processing Outperforms Chemical Extraction

7. Commercial Implementation: MacroAlga Product Portfolio

References

1. Miao J, et al. Comparative research of plant hormones and alginate oligosaccharides in seaweed extracts. South China Fisheries Science. 2022.
2. Jouanneau M, et al. Enzyme-assisted extraction on Fucus vesiculosus. Journal of Applied Phycology. 2024.
3. Zhang X, et al. Low-cost and efficient strategy for brown algal hydrolysis. Bioresource Technology. 2024.
4. Sun C, et al. Hydrolyzing Laminaria japonica with microbial alginate lyase and cellulase. Bioresource Technology. 2020.
5. National Pesticide Quality Supervision & Inspection Center (SARCCI). COS test report. 2022.
6. Jiangnan University Analysis & Testing Center. Report JC23091308807: AOS DP quantification by MS.
7. CTI Testing. Report A2230097391101001C: Amino acid composition of blood peptide powder.
8. Enterprise Standards Q/370785MKAJ-001-2021 (COS & AOS).